Sentence examples for formulation candidate from inspiring English sources

The gelation of the lead formulation candidate at 37°C was measured as distance traveled after application to a tilted Petri dish.

To avoid possible confusing effects due to the formulation, candidate NTSR contigs were selected on the basis of an up-regulation ≥ 2-fold in the resistant pool compared to the sensitive pool at each time-point including UT. Affiliation of candidate contigs to one gene family presumably involved in NTSR was an additional selection criterion.

Two lead formulation candidates were selected based on their predicted stability profile.

Incorporation of new models, assays and biomarkers has expanded our ability to understand the mechanisms of action underlying microbicide toxicity and efficacy, enabling a more rational selection of drug and formulation candidates.

Once potential formulation candidates are achieved, automation in mixing, tableting and packaging should be done in a low humidity and controlled room temperature environment, and subject the final products to stability study in controlled room temperature and relative humidity of the countries to be marketed.

In fact, the World Health Organization (WHO) recommendations for the 2011 2012 northern hemisphere seasonal influenza vaccine formulation already identify candidate vaccine strains from both influenza B lineages.

In product development, it is used to assist in the selection of a candidate formulation, in research to detect the influence of critical manufacturing variables, such as the binder effect, mixing effect, granulation procedure, coating parameters, and excipient type [ 1].

Yet, a combination of increased stability together with specific features of WIV which promote vaccine availability, like strong immunogenicity, dose sparing quality and manufacturing simplicity (46), make dry-powder WIV an apt candidate formulation for pre-pandemic stockpiling.

To the best of our knowledge, the CAP film is presently the first film formulation for a candidate microbicide after the failure of an N-9 containing contraceptive film in phase III clinical trials for efficacy against sexual transmission of HIV-1.

The rationale for reporting these two studies together is to characterize the immunogenicity, reactogenicity, and safety of the QIV candidate formulation alongside that of the TIV to evaluate the acceptability of the new manufacturing process particularly regarding the European Union Committee for Medicinal Products for Human Use (CHMP) immunogenicity acceptance criteria.

Candidate formulations must satisfy necessary and sufficient conditions.